Georgina Venetia LongAO (born 15 November 1970[citation needed]) is an Australian oncologist, clinical trialist and translational researcher, and works in drug therapy development. Long was the first woman and first Australian to be named president of the US-based Society for Melanoma Research.[1]
Long had five siblings and grew up in Sydney's inner west. She also lived in Europe and America as a child.[3] She completed high school at Santa Sabina College in 1988.[4]
Long began studying a combined degree of science and law at the University of Sydney, but gave up law and graduated with a double major in pure maths and chemistry in 1993, before completing a PhD in organic chemistry, also at Sydney University, in 1996.[5][6] She was a postdoctoral researcher at the Scripps Research Institute in California as a Fulbright Fellow, before returning to Australia to undertake her medical degree, graduating with an MBBS in 2001.[5][6]
Career
Long is a medical oncologist specialising in melanoma. She has led numerous clinical trials,[7][8] focusing on targeted therapies and immuno-oncology in melanoma.[9] She is the chief investigator on research into the molecular biology of melanoma.[10]
Long is Director of the Melanoma Institute Australia. Together with pathologist Richard Scolyer, they have been part of a team pioneering the use of immunotherapy treatment for melanoma, which Long then adapted for brain cancer when Scolyer was diagnosed with it in June 2023.[11][12] He was the first brain cancer patient in the world to have pre-surgery combination immunotherapy.[13][14]
↑ Blank, Christian U.; Lucas, Minke W.; Scolyer, Richard A.; van de Wiel, Bart A.; Menzies, Alexander M.; Lopez-Yurda, Marta; Hoeijmakers, Lotte L.; Saw, Robyn P. M.; Lijnsvelt, Judith M.; Maher, Nigel G.; Pulleman, Saskia M.; Gonzalez, Maria; Torres Acosta, Alejandro; van Houdt, Winan J.; Lo, Serigne N. (7 November 2024). "Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma". The New England Journal of Medicine. 391 (18): 1696–1708. doi:10.1056/NEJMoa2402604. ISSN1533-4406. PMID38828984.
↑ Ertl, Carolin; Ruf, Theresa; Mentzer, Dirk; Kong, Mingzi; Kramer, Rafaela; Bergwelt-Baildon, Michael von; Subklewe, Marion; Tomsitz, Dirk; Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen; Lebbé, Celeste; Long, Georgina V.; McArthur, Grant; Neilan, Tomas G. (March 2024). "The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects". European Journal of Cancer. 199 113505. doi:10.1016/j.ejca.2023.113505. ISSN1879-0852. PMID38262306.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
